BACKGROUND: Comorbidity is an important prognostic factor for survival in other cancers, but the importance in soft tissue sarcoma has not yet been clarified. The aims of this study were to examine the prevalence of comorbidity in soft tissue sarcoma patients, and estimate the impact of comorbidity on overall and disease-specific mortality. MATERIAL AND METHODS: Overall, 1210 adult patients with soft tissue sarcoma in the extremities or trunk wall were identified through the Aarhus Sarcoma Registry, a validated population-based database. Information on comorbidity was obtained through the National Patient Registry, and a Charlson's Comorbidity score was calculated for each patient. The prevalence of comorbidity was assessed overall, as well as according to age and year of diagnosis. Overall and disease-specific mortality rates according to level of comorbidity were computed. The prognostic value of comorbidity was estimated using crude and adjusted Cox proportional hazard models. RESULTS: The overall prevalence of comorbidity was 25%. The prevalence increased with increasing age, and patients with comorbidity had a larger proportion of adverse prognostic factors when compared to patients without comorbidity. The five-year disease-specific mortality was 26% (95% CI 24-29) for patients without comorbidity, compared to 33% (95% CI 24-42), 41% (95% CI 32-50), and 44% (95% CI 33-55) for patients with mild, moderate, and severe comorbidity, respectively. After adjusting for age, sex, stage, tumor size, depth, grade, surgical margin, radiotherapy, and chemotherapy, comorbidity was independently associated with an increased overall and disease-specific mortality. CONCLUSION: Patients with comorbidity had significantly increased overall and disease-specific mortality compared to patients without comorbidity, even when adjusting for important prognostic factors including age.
BACKGROUND: Comorbidity is an important prognostic factor for survival in other cancers, but the importance in soft tissue sarcoma has not yet been clarified. The aims of this study were to examine the prevalence of comorbidity in soft tissue sarcomapatients, and estimate the impact of comorbidity on overall and disease-specific mortality. MATERIAL AND METHODS: Overall, 1210 adult patients with soft tissue sarcoma in the extremities or trunk wall were identified through the Aarhus Sarcoma Registry, a validated population-based database. Information on comorbidity was obtained through the National Patient Registry, and a Charlson's Comorbidity score was calculated for each patient. The prevalence of comorbidity was assessed overall, as well as according to age and year of diagnosis. Overall and disease-specific mortality rates according to level of comorbidity were computed. The prognostic value of comorbidity was estimated using crude and adjusted Cox proportional hazard models. RESULTS: The overall prevalence of comorbidity was 25%. The prevalence increased with increasing age, and patients with comorbidity had a larger proportion of adverse prognostic factors when compared to patients without comorbidity. The five-year disease-specific mortality was 26% (95% CI 24-29) for patients without comorbidity, compared to 33% (95% CI 24-42), 41% (95% CI 32-50), and 44% (95% CI 33-55) for patients with mild, moderate, and severe comorbidity, respectively. After adjusting for age, sex, stage, tumor size, depth, grade, surgical margin, radiotherapy, and chemotherapy, comorbidity was independently associated with an increased overall and disease-specific mortality. CONCLUSION:Patients with comorbidity had significantly increased overall and disease-specific mortality compared to patients without comorbidity, even when adjusting for important prognostic factors including age.
Authors: Rachel K Voss; Yi-Ju Chiang; Keila E Torres; B Ashleigh Guadagnolo; Gary N Mann; Barry W Feig; Janice N Cormier; Christina L Roland Journal: Ann Surg Oncol Date: 2017-07-24 Impact factor: 5.344
Authors: R L Jones; G D Demetri; S M Schuetze; M Milhem; A Elias; B A Van Tine; J Hamm; S McCarthy; G Wang; T Parekh; R Knoblauch; M L Hensley; R G Maki; S Patel; M von Mehren Journal: Ann Oncol Date: 2018-09-01 Impact factor: 32.976
Authors: Mathias Rædkjær; Katja Maretty-Kongstad; Thomas Baad-Hansen; Akmal Safwat; Michael M Petersen; Johnny Keller; Peter Vedsted Journal: Sarcoma Date: 2019-05-07
Authors: Hyo Song Kim; Chung Mo Nam; Suk-Yong Jang; Sun Kyu Choi; Minkyung Han; Seonmin Kim; Maria Victoria Moneta; Sae Young Lee; Jae Min Cho; Diego Novick; Sun Young Rha Journal: Cancer Res Treat Date: 2019-02-18 Impact factor: 4.679
Authors: Eugenie Younger; Olga Husson; Lindsey Bennister; Jeremy Whelan; Roger Wilson; Andy Roast; Robin L Jones; Winette Ta van der Graaf Journal: BMC Cancer Date: 2018-10-17 Impact factor: 4.430